The role of antioxidants in the therapy of metabolic syndrome in men

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Introduction. Metabolic syndrome (MetS) is a combination of hormonal, metabolic and clinical disorders. Currently, MetS in men is considered as one of the main risk factors for the development of cardiovascular diseases, insulin resistance, and pathology of the reproductive system.

Aim. To study the effect of a complex of folic acid, L-carnitine, vitamin E, zinc and selenium, which are part of the biologically active food supplement «Speroton», on the parameters of carbohydrate and lipid metabolism in men with MetS, especially in the early stages of its development, as well as on erectile function and quality of life of patients.

Materials and methods. A total of 64 patients aged 30 to 51 years with MetS of varying severity were included in the study. The main group consisted of 34 patients aged 32 to 51 years (mean age 46.2±2.1 years), while in the control group, there were 30 patients aged 30 to 49 years (mean age 45.4±3.4 years). The standard therapy in the main group was supplemented by taking the dietary supplement «Speroton» for 3 months. In the control group, patients received only standard therapy for MetS. The results were evaluated after 3 and 6 months from the start of treatment.

All patients underwent laboratory evaluation of sex hormones, carbohydrate metabolism and lipid profile. In addition, the concentration of zinc in the spermatozoa was measured, as well as the level of total antioxidant capacity of the sperm. The uroflowmetry, ultrasound of the bladder with the measurement of the postvoid residual, and transrectal ultrasound of the prostate were also performed.

Results. An addition of the antioxidant complex «Speroton» to the combination treatment of MetS in the main group allowed to decrease the parameters of oxidative stress by almost two times. By the 6th month of follow-up, the level of insulin improved, which was accompanied by a decrease in the level of HbA1c by 16.3%, suggesting the stabilization of carbohydrate metabolism. A decrease in body mass index by almost 14% (p<0.05) in the main group was found, as well as normalization of the lipid profile. According to the analysis of the erectile function in patients of the main group after 6 months from the beginning of therapy, there was a decrease in the total score to a moderate erectile dysfunction (12.5±2.1 points). There was a decrease in storage symptoms and, in part, voiding symptoms in patients in the main group, who received antioxidant therapy. In addition, a positive correlation between the concentration of zinc and the level of total antioxidant capacity in the ejaculate was seen.

Conclusions: Our results suggest the high therapeutic efficiency of dietary supplement «Speroton» as an antioxidant complex for the treatment of patients with MetS of varying severity. The addition of antioxidants «Speroton» to the standard therapy of MetS contributes to the improvement of the sensitivity of insulin receptors, the normalization of carbohydrate and lipid metabolism, endothelial function and blood pressure, which is accompanied by a significant decrease in LUTS severity, as well as an improvement in the erectile function of patients.

Sobre autores

N. Nashivochnikova

1Privolzhsky Research Medical University of the Ministry of Health of the Russia

Autor responsável pela correspondência
Email: dom17.doctor@mail.ru
ORCID ID: 0000-0002-1138-1174

Ph.D., associate professor at the Department of Urology named after E.V. Shakhov of Privolzhsky Research Medical University of the Ministry of Health of the Russia

Rússia, Nizhny Novgorod

V. Krupin

Privolzhsky Research Medical University of the Ministry of Health of the Russia

Email: dom17.doctor@mail.ru
ORCID ID: 0000-0002-4887-4888

Ph.D., MD, professor, Head of the Department of Urology named after E.V. Shakhov of Privolzhsky Research Medical University of the Ministry of Health of the Russia

Rússia, Nizhny Novgorod

V. Leanovich

JSC «Akvion»

Email: leanovichVE@akvion.ru
ORCID ID: 0000-0001-7653-797X

medical director of JSC «Akvion»

Rússia, Moscow

Bibliografia

  1. Serebrennikova S.N., Guzovskaya E.V., Seminsky I.J. Pathophysiology of metabolic syndrome: textbook. FGBOU VO IGMU of the Ministry of Health of Russia, Department of Pathological Physiology with a course of clinical immunology. Irkutsk: IGMU, 2016. p. 54. Russian (Серебренникова С.Н., Гузовская Е.В., Семинский И.Ж. Патофизиология метаболического синдрома: учебное пособие. ФГБОУ ВО ИГМУ Минздрава России, Кафедра патологической физиологии с курсом клинической иммунологии. Иркутск: ИГМУ, 2016. С. 54).
  2. Borisov V. V., Demerza Yu. A. Features of treatment of patients with erectile dysfunction. The attending physician. 2005;10: 86–89. Russian (Борисов В.В., Демерза Ю.А. Особенности лечения больных эректильной дисфункцией. Лечащий врач. 2005;10: 86–89).
  3. Mammadov M.N., Perova N.V., Metelskaya V.A., Oganov R.G. Cardiology. M., 1999. pp. 18-22. Russian (Мамедов М.Н., Перова Н.В., Метельская В.А., Оганов Р.Г. Кардиология. М., 1999. С. 18–22).
  4. Vignozzi L., Morelli A., Sarchielli E., Comeglio P., Filippi S., Cellai I., Maneschi E. et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012; 212(1):71–84. doi: 10.1530/JOE-11-0289.
  5. Bratchikov O.I., Tyuzikov I.A., Shumakova E.A., Artishchev S.O. Symptoms from the lower urinary tract caused by prostate adenoma: treatment results depending on the androgenic status. Andrology and genital surgery. 2018;19(1):51–58. doi: 10.17650/2070-9781-2018-19-1-51-58. Russian (Братчиков О.И., Тюзиков И.А., Шумакова Е.А., Артищев С.О. Симптомы со стороны нижних мочевых путей, вызванные аденомой предстательной железы: результаты лечения в зависимости от андрогенного статуса. Андрология и генитальная хирургия. 2018;19(1):51–58. doi: 10.17650/2070-9781-2018-19-1-51-58).
  6. Tyuzikov I.A. Pathogenetic mechanisms of the effect of testosterone deficiency on the symptoms of the lower urinary tract in men. Effective pharmacotherapy. 2020;16(20):32–42. doi: 10.33978/2307-3586-2020-16-20-32-42. Russian (Тюзиков И.А. Патогенетические механизмы влияния дефицита тестостерона на симптомы нижних мочевых путей у мужчин. Эффективная фармакотерапия. 2020;16(20):32–42. doi: 10.33978/2307-3586-2020-16-20- 32-42).
  7. Makolkin V.I. Metabolic syndrome. Moscow: MIA, 2010. pp. 3-143. Russian (Маколкин В.И. Метаболический синдром. М.: МИА, 2010. С. 3–143).
  8. Aronov D.M. What is important for a practicing doctor to know about ubiquinone. Antioxidant drug Kudesan. M.: Medical practice. 2006;2:4–20. Russian (Аронов Д.М. Что важно знать практикующему врачу об убихиноне. Антиоксидантный препарат Кудесан. М.: Медпрактика. 2006;2:4–20).
  9. Dedov I.I., Balabolkin M.I., Mamaeva G.G., etc. Antioxidant therapy of diabetes and its late complications. Manual for doctors. M., 2001. pp. 24–27. Russian (Дедов И.И., Балаболкин М.И., Мамаева Г.Г. и др. Антиоксидантная терапия диабета и его поздних осложнений. Пособие для врачей. М., 2001. С. 24–27).
  10. Lankin V.Z., Tikhase A.K., Belenkov Yu.N. Antioxidants in the complex therapy of atherosclerosis: pro et contra. Manual for doctors. M.: Medical practice. 2006. pp. 3-39. Russian (Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: pro et contra. Пособие для врачей. М.: Медпрактика. 2006. С. 3–39).
  11. Mortensen S. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of Q-symbio-a multinational trial Biofactors. 2003;18(1–4):79–89.
  12. Trukhan D.I. The role and place of L-carnitine in cytoprotection and correction of metabolic processes in patients with metabolic syndrome. Medical advice. 2017;12:182–187. Russian (Трухан Д.И. Роль и место L-карнитина в цитопротекции и коррекции метаболических процессов у пациентов с метаболическим синдромом. Медицинский совет. 2017;12:182–187).
  13. Astashkin E.I., Glezer M.G. The role of L-carnitine in the energy metabolism of cardiomyocytes and the treatment of diseases of the cardiovascular system. Cardiology and cardiovascular surgery. 2012;5(6):58–65. Russian (Асташкин Е.И., Глезер М.Г. Роль L-карнитина в энергетическом обмене кардиомиоцитов и лечении заболеваний сердечно-сосудистой системы. Кардиология и сердечно-сосудистая хирургия. 2012;5(6):58–65).
  14. Lohninger A., Pittner G., Pittner F. L-Carnitine: New Aspects of a Known Compound – A Brief Survey. Monatsh. Chem. 2005;136(8):1255–1268.
  15. Surai P.F. Antioxidant action of carnitine: molecular mechanisms and practical applications. EC Veterinary Science. 2015;2(1):66–84.
  16. Klyuchnikov S.O. Prospects for the use of L-carnitine in pediatrics. Consilium Medicum. 2007;2:116–119. Russian (Ключников С.О. Перспективы применения L-карнитина в педиатрии. Consilium Medicum. 2007;2:116–119).
  17. Markelova I.A., Balykova L.A. and others. The use of metabolic therapy to optimize the tolerance of young athletes to physical exertion. Pediatrics. 2008;4:51–55. Russian (Маркелова И.А., Балыкова Л.А. и др. Применение метаболической терапии для оптимизации толерантности юных спортсменов к физическим нагрузкам. Педиатрия. 2008;4:51–55).
  18. Balykova L.A., Soldatov O.M., Ivyansky L.A., Ferapontova O.V. Justification of the use of L-carnitine in sports medicine. Russian Bulletin of Perinatology and Pediatrics. 2010;5:90–97. Russian (Балыкова Л. А., Солдатов О. М., Ивянский Л. А., Ферапонтова О. В. Обоснование использования L-карнитина в спортивной медицине. Российский вестник перинатологии и педиатрии. 2010;5:90–97).
  19. Ivyansky S.A., Soldatov O.M., Shchekina N.V., etc. New aspects of the use of L-carnitine in sports practice. Ulyanovsk Medical and Biological Journal. 2012;3:97–103. Russian (Ивянский С.А., Солдатов О.М., Щёкина Н.В. и др. Новые аспекты применения L-карнитина в спортивной практике. Ульяновский медико-биологический журнал. 2012;3:97–103).
  20. Sachan D.S., Yatim A.M. Suppression of aflatoxin B1-induced lipid abnormalities and macromolecule-adduct formation by L-carnitine. J Environ Pathol Toxicol Oncol. 1992;11:205–210.
  21. Balykova L.A., Ivyansky S., Shirokova A. et al. Assessment of blood pressure levels in children involved in regular sports. Pediatrics. The magazine named after G.N. Speransky. 2015;6:113–119. Russian (Балыкова Л.А., Ивянский С., Широкова А. и др. Оценка уровня артериального давления у детей, привлеченных к регулярным занятиям спортом. Педиатрия. Журнал им. Г.Н. Сперанского. 2015;6:113–119).
  22. Sycheva Yu.A., Gorbacheva I.A., Orekhova L.Yu. The use of metabolic therapy in polymorbid patients with inflammatory periodontal diseases on the background of hypertension. Periodontology. 2016;2(79):39–42. Russian (Сычева Ю.А., Горбачева И.А., Орехова Л.Ю. Применение метаболической терапии у полиморбидных больных с воспалительными заболеваниями пародонта на фоне гипертонической болезни. Пародонтология. 2016;2(79):39–42).
  23. Xu Y., Jiang W., Chen G. et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. Adv Clin Exp Med. 2017;26(2):333–338.
  24. Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci. 2004;1033: 99–107.
  25. Rahbar A.R., Shakerhosseini R., Saadat N. et al. Effect of L-carnitine on plasma glycemic andlipidemic profile in patients with type II diabetes mellitus. Eur J Clin Nutr. 2005;59:592–596.
  26. Kapelko V.I. Reactive oxygen species, antioxidants and prevention of heart diseases. RMZH. 2003;11(21):1185-1188. Russian (Капелько В.И. Активные формы кислорода, антиоксиданты и профилактика заболеваний сердца. РМЖ. 2003;11(21):1185–1188).
  27. Adarsh K., Kaur H., Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). BioFactors (Oxford, England). 2008;32(1–4):145–149.
  28. Mortensen S. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of Q-symbio-a multinational trial Biofactors. 2003;18(1–4):79–89.
  29. Shikh E.V., Makhova A.A. Vitamins in clinical practice. M.: Practical Medicine, 2014. Russian (Ших Е.В., Махова А.А. Витамины в клинической практике. М.: Практическая медицина, 2014).
  30. Tato Rocha R.E., Cárdenas Viedma E., Herrero Huerta E. Selenium: the physiopathological and clinical implications. An. Med. Interna. 1994;11(9):457–463.
  31. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association. 2001;285:2486–2497.
  32. Condorelli R.A., Russo G.I., Calogero A.E. et al. Chronic prostatitis and its detrimental impact on sperm parameters: a systematic review and meta-analysis. J. Endocrinol. Invest. 2017;40(11):1209–1218.
  33. Huang M.Y., Wang M.Y., Lin Y.S., Lin C.J., Lo K., Chang I.J., Cheng T.Y. et al. The Association between Metabolically Healthy Obesity, Cardiovascular Disease, and All-Cause Mortality Risk in Asia: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020; 17(4):1320. doi: 10.3390/ijerph17041320.
  34. Yassin A.A., Nettleship J.E., Almehmadi Y., Yassin D.J., El Douaihy Y., Saad F. Is there a relationship between the severity of erectile dysfunction and the comorbidity profile in men with late onset hypogonadism? Arab J Urol. 2015;13(3):162–68. doi: 10.1016/j.aju.2015.06.003.
  35. Shkodkin S., Idashkin Y., Shaderkin I., Shaderkina V., Polishchuk A., Chirkov S. Transurethral resection of benign prostatic hyperplasia and impaired miccia. J. Experimental and clinical Urology. 2017;(2):68–72.
  36. Bratchikov O.I., Dubonos P.A., Tyuzikov I.A. Features of zinc metabolism and its relationship with the oxidative status of the prostate gland in healthy men and patients with chronic bacterial prostatitis. Effective pharmacotherapy. 2021;17(17):6–14. Russian (Братчиков О.И., Дубонос П.А., Тюзиков И.А. Особенности обмена цинка и его связь с оксидативным статусом предстательной железы у здоровых мужчин и больных хроническим бактериальным простатитом. Эффективная фармакотерапия. 2021;17(17):6–14).

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2023

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies